Feedback

Browsing by K

Use an asterisk (*) for partial word searches (e.g. pemph*)

26 results found.

1.
Ordering Recommendation:  

Assess adrenal androgen production. Preferred test is Dehydroepiandrosterone Sulfate, Serum (0070040).

2.
Ordering Recommendation:  

Confirm diagnosis of Kabuki syndrome.

3.
Ordering Recommendation:  

Aids in the diagnosis of multiple myeloma and related disorders. Preferred test is the quantitative test (Kappa and Lambda Free Light Chains (Bence Jones Protein), Quantitative, Urine (0050618)).

4.
Ordering Recommendation:  

Aids in the diagnosis and management of multiple myeloma and related disorders. Preferred test to detect and quantify urinary free light chains (Bence Jones protein).

5.
Ordering Recommendation:  

Quantify and determine clonality of free kappa light chains (Bence Jones protein) in urine.

6.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

7.
Ordering Recommendation:  

Quantify kappa and lambda light chains in paraffin. Includes interpretation.

8.
Ordering Recommendation:  

Quantify kappa and lambda light chains in paraffin. Does not include interpretation.

9.
Ordering Recommendation:  

Aid in evaluation and management of multiple myeloma and related plasma cell disorders. Indicated for the diagnosis of patients with oligosecretory or nonsecretory multiple myeloma and light chain amyloidosis.

10.
Ordering Recommendation:  

Initial screen for K antigen status.

11.
Ordering Recommendation:  

Assess risk for alloimmune hemolytic disease of the newborn or hemolytic transfusion reaction. May be ordered for parental or fetal genotyping.

12.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

13.
Ordering Recommendation:  

Screening and monitoring of patients with suspected Morquio syndrome (MPS IV), in conjunction with other mucopolysaccharides screen tests.

14.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

15.
16.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

17.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

18.
Ordering Recommendation:  

May use to monitor kidney stone formation. Panel includes calcium, citric acid, creatinine, oxalate, and uric acid. Preferred test is Supersaturation Profile, Urine (2008771) or Calculi Risk Assessment, Urine (2008708).

19.
Ordering Recommendation:  

Aid in the diagnosis of mastocytosis. Provide prognostic and predictive information for tyrosine kinase inhibitor (TKI) therapy planning.

20.
Ordering Recommendation:  

Humanitarian Device. Authorized by Federal law for use in qualitative polymerase chain reaction (PCR) detection of KIT D816V mutational status in patients with aggressive systemic mastocytosis (ASM). The effectiveness of this device for this use has not been demonstrated. Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner.

KIT D816V Mutation Detection by PCR for Gleevec Eligibility in Aggressive Systemic Mastocytosis (ASM) is an in vitro diagnostic test intended for qualitative polymerase chain reaction (PCR) detection of KIT D816V mutational status from fresh bone marrow samples of patients with aggressive systemic mastocytosis. The KIT D816V mutational assay is indicated as an aid in the selection of ASM patients for whom Gleevec (imatinib mesylate) treatment is being considered. This assay is for professional use only and is to be performed at a single laboratory site.

21.
Ordering Recommendation:  

Prognostication in core-binding factor-related (CBF) AML.

22.
Ordering Recommendation:  

Detect activating mutations in KIT and PDGFRA. Predict response to tyrosine kinase inhibitor (TKI) therapy. 

23.
24.
25.
Ordering Recommendation:  

Predicts response to anti-EGFR and MAPK pathway therapies in a variety of malignancies (eg,  colorectal and lung cancer).

26.
Ordering Recommendation:  

Determine eligibility for anti-EGFR (cetuximab and panitumumab) therapy in patients with metastatic colorectal cancer.